Temenos named Technology Provider of the Year in FStech Awards
GRAND-LANCY, Switzerland, March 21, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN) today announced it has been named Technology Provider of the Year at the FStech Awards 2025, recognizing its leadership in modernizing financial institutions with banking solutions powered by GenAI, cloud, and SaaS.
Now in their 25th year, the FStech Awards celebrate companies that have demonstrated excellence and innovation within the UK and EMEA financial services sector. In the Technology Provider of the Year category, judges evaluated vendors based on their exceptional performance, product innovations, and customer success.
Mark Yamin-Ali, Managing Director - Europe, Temenos, commented: 'This FStech award underscores Temenos' leadership in core banking modernization and our reputation as a trusted industry partner. With proven expertise and reliable innovation, including in game-changing technologies such as Generative AI, Temenos enables banks to evolve with confidence, fostering growth and elevating customer experiences.'
Sairam Rangachari, Chief Product Officer, Temenos, said: 'We're delighted to receive this prestigious award, which recognizes the rich functionality of Temenos' mission-critical technology. With our relentless focus on innovation, as well as our leading SaaS solutions and Responsible AI capabilities embedded throughout the Temenos platform, we are thrilled to be leading the way in the banking industry.'
Banks of all sizes utilize Temenos' adaptable technology – on-premises, in the cloud, or as a SaaS solution – to deliver next-generation services and AI-powered experiences. Its clients benefit from the power of deep functionality, the convenience of best-of-suite software and the synergy of modular solutions.
Recent customer announcements include the UK's Aldermore Bank, which selected Temenos SaaS to modernize its savings operations, beginning with the swift launch of new savings notice accounts for small businesses. Additionally, Romania's CEC Bank selected Temenos to modernize its retail and corporate core banking systems.
About TemenosTemenos (SIX: TEMN) is the world's leading platform for banking, serving clients in 150 countries by helping them build new banking services and state-of-the-art customer experiences. Top performing banks using Temenos software achieve cost-income ratios almost half the industry average and returns on equity 2x the industry average. Their IT spend on growth and innovation is also 2x the industry average.
For more information, please visit www.temenos.com.
Media Contacts
Scott Rowe & Michael AndersonTemenos Global Public Relations Tel: +44 20 7423 3857Email: press@temenos.com
Gabriel GoonetillakeTemenos Team at Edelman SmithfieldTel: +44 7813 407710Temenos@EdelmanSmithfield.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Beverage Carton Packaging Machinery Market 2025-2030: Shift to Renewable and Biodegradable Carton Materials Requiring Specialized Packaging Machinery Presents Lucrative Opportunities
Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "Beverage Carton Packaging Machinery Market by Application (Dairy Products, Juice, Milk), Packaging Technology (Aseptic, Non Aseptic), Machine Type, Material Type, Automation Level, Speed, End User - Global Forecast 2025-2030" report has been added to offering. The beverage carton packaging machinery market is undergoing rapid transformation as sustainability pressures, automation adoption, and regulatory changes drive new operational priorities for global producers and equipment suppliers. Industry leaders and decision-makers must adapt promptly to capture growth, manage risks, and deliver efficient, compliant packaging solutions that align with evolving consumer expectations. Market Snapshot: Beverage Carton Packaging Machinery In the latest assessment, the beverage carton packaging machinery market grew from USD 1.18 billion in 2024 to USD 1.24 billion in 2025. Driven by strong demand for sustainable and automated packaging equipment, the sector is forecast to advance at a CAGR of 5.63%, reaching USD 1.64 billion by 2030. This steady expansion is underpinned by consumer demands for convenience, stricter food safety laws, and technological enhancements across end markets. Scope & Segmentation of the Beverage Carton Packaging Machinery Market Applications: Equipment supporting dairy products (flavored milk and yogurt drinks), juices (fruit and vegetable), and milk processing (pasteurized and UHT varieties). Packaging Technologies: Both aseptic (high temperature short time, ultra high temperature) and non-aseptic (ambient, refrigerated) processes are included. Machine Types: Solutions encompassing capping, carton loading and unloading, horizontal and vertical form fill seal, and advanced sterilization featuring chemical or thermal techniques. Material Types: Composite (laminate and multilayer), paperboard (recycled, virgin), and plastics (HDPE, PET) configurations are addressed. Automation Levels: Fully automatic systems (PLC controlled and robotic), as well as manual and semi-automatic machinery, cater to diverse operational needs. Speed Categories: High, medium, and low-speed machines allow for flexibility across varying production volumes. End User Profiles: Solutions are tailored for large-scale producers, contract packagers, in-house operations, and small-scale enterprises seeking compact equipment. Regional Coverage: In-depth analysis for Americas (including United States, Canada, Brazil, and others), Europe, Middle East & Africa (covering major economies and emerging territories), and Asia-Pacific (China, India, Japan, and key Southeast Asian countries). Leading Companies: Competitive analysis of providers such as Tetra Pak International S.A., SIG Group AG, Elopak AS, Krones AG, GEA Group Aktiengesellschaft, KHS GmbH, Syntegon Technology GmbH, IMA Dairy & Food S.p.A., Serac Group SAS, and MULTIVAC Sepp Haggenmuller SE & Co. KG. Key Takeaways Consumer demand for lighter, recyclable packaging is directing material R&D priorities, prompting manufacturers to enhance compatibility with new paperboard and polymer substrates. Sustainable manufacturing strategies are shifting toward renewable energy utilization, supported by regulatory pressures and growing environmental targets across developed and emerging economies. Industry 4.0 and digitalization initiatives are enabling real-time performance monitoring, predictive maintenance, and seamless enterprise integration, resulting in greater process efficiency and transparency. Automation and robotics, including advanced vision systems and modular platforms, are reducing labor requirements and optimizing throughput for varied production cycles and product launches. Collaborative supplier and fabrication networks are emerging as essential for managing raw material cost volatility and shortening equipment delivery timelines, particularly under jurisdictional disruptions. Impact of 2025 United States Tariffs The 2025 US tariffs on machinery components and raw materials have intensified cost management challenges for original equipment manufacturers and producers. Strategic responses include localizing supply chains, optimizing material usage, and establishing contractual partnerships with regional suppliers to maintain competitive pricing. This environment places pressure on small and medium-sized businesses, making agility and supply chain resilience crucial for ongoing market participation. Methodology & Data Sources This report combines insights from direct interviews with key supply chain stakeholders, including equipment manufacturers and plant managers, alongside comprehensive reviews of technical journals, regulatory filings, patent databases, and industry whitepapers. Data triangulation and benchmarking further strengthen the accuracy of segmentation and trend analyses. Beverage Carton Packaging Machinery Market: Why This Report Matters Enables leaders to benchmark their strategies against evolving industry standards and regulatory requirements for both sustainability and automation. Delivers actionable segmentation and technology-specific guidance, supporting capital allocation and operational planning across diverse end uses and regions. Key Attributes Report Attribute Details No. of Pages 182 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.24 Billion Forecasted Market Value (USD) by 2030 $1.64 Billion Compound Annual Growth Rate 5.6% Regions Covered Global Key Topics Covered1. Preface1.1. Objectives of the Study1.2. Market Segmentation & Coverage1.3. Years Considered for the Study1.4. Currency & Pricing1.5. Language1.6. Stakeholders2. Research Methodology2.1. Define: Research Objective2.2. Determine: Research Design2.3. Prepare: Research Instrument2.4. Collect: Data Source2.5. Analyze: Data Interpretation2.6. Formulate: Data Verification2.7. Publish: Research Report2.8. Repeat: Report Update3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics5.1. Adoption of digital twin technology for real-time carton packaging line optimization5.2. Integration of AI-powered vision inspection systems to minimize defects in beverage cartons5.3. Implementation of aseptic high-speed filling modules to extend shelf life of sensitive beverages5.4. Shift to renewable and biodegradable carton materials requiring specialized packaging machinery5.5. Deployment of modular packaging line architectures for rapid product changeovers and flexibility5.6. Incorporation of servo-driven energy-efficient carton erectors to lower overall production costs5.7. Integration of Industry 4.0 analytics platforms for comprehensive machinery performance insights5.8. Adoption of collaborative robotics for customizable case and carton packing operations5.9. Upgrading packaging machinery to meet stringent global food safety and hygiene regulatory requirements5.10. Design of ultra-compact packaging equipment footprints for urban micro-facility deployments6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. Beverage Carton Packaging Machinery Market, by Application8.1. Introduction8.2. Dairy Products8.2.1. Flavored Milk8.2.2. Yogurt Drinks8.3. Juice8.3.1. Fruit Juice8.3.2. Vegetable Juice8.4. Milk8.4.1. Pasteurized Milk8.4.2. UHT Milk9. Beverage Carton Packaging Machinery Market, by Packaging Technology9.1. Introduction9.2. Aseptic9.2.1. High Temperature Short Time9.2.2. Ultra High Temperature9.3. Non Aseptic9.3.1. Ambient9.3.2. Refrigerated10. Beverage Carton Packaging Machinery Market, by Machine Type10.1. Introduction10.2. Capping10.3. Carton Loading Unloading10.4. Form Fill Seal10.4.1. Horizontal Form Fill Seal10.4.2. Vertical Form Fill Seal10.5. Sterilization10.5.1. Chemical Sterilization10.5.2. Thermal Sterilization11. Beverage Carton Packaging Machinery Market, by Material Type11.1. Introduction11.2. Composite11.2.1. Laminate11.2.2. Multilayer11.3. Paperboard11.3.1. Recycled Paperboard11.3.2. Virgin Paperboard11.4. Plastic11.4.1. HDPE11.4.2. PET12. Beverage Carton Packaging Machinery Market, by Automation Level12.1. Introduction12.2. Fully Automatic12.2.1. PLC Controlled12.2.2. Robotic12.3. Manual12.4. Semi Automatic13. Beverage Carton Packaging Machinery Market, by Speed13.1. Introduction13.2. High Speed13.3. Low Speed13.4. Medium Speed14. Beverage Carton Packaging Machinery Market, by End User14.1. Introduction14.2. Large Scale Producers14.2.1. Contract Packagers14.2.2. In House Packaging14.3. Small Scale Producers15. Americas Beverage Carton Packaging Machinery Market15.1. Introduction15.2. United States15.3. Canada15.4. Mexico15.5. Brazil15.6. Argentina16. Europe, Middle East & Africa Beverage Carton Packaging Machinery Market16.1. Introduction16.2. United Kingdom16.3. Germany16.4. France16.5. Russia16.6. Italy16.7. Spain16.8. United Arab Emirates16.9. Saudi Arabia16.10. South Africa16.11. Denmark16.12. Netherlands16.13. Qatar16.14. Finland16.15. Sweden16.16. Nigeria16.17. Egypt16.18. Turkey16.19. Israel16.20. Norway16.21. Poland16.22. Switzerland17. Asia-Pacific Beverage Carton Packaging Machinery Market17.1. Introduction17.2. China17.3. India17.4. Japan17.5. Australia17.6. South Korea17.7. Indonesia17.8. Thailand17.9. Philippines17.10. Malaysia17.11. Singapore17.12. Vietnam17.13. Taiwan18. Competitive Landscape18.1. Market Share Analysis, 202418.2. FPNV Positioning Matrix, 202418.3. Competitive AnalysisThe major companies profiled in this Beverage Carton Packaging Machinery market report include: Tetra Pak International S.A. SIG Group AG Elopak AS Krones AG GEA Group Aktiengesellschaft KHS GmbH Syntegon Technology GmbH IMA Dairy & Food S.p.A. Serac Group SAS MULTIVAC Sepp Haggenmuller SE & Co. KG For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
5 hours ago
- Business Wire
Develop Health Raises $14.3M to Automate Prior Authorization and Medication Access Using GenAI
SAN FRANCISCO--(BUSINESS WIRE)-- Develop Health, an EHR-integrated benefits‑verification and prior‑authorization platform, today announced a $14.3 million Series A led by Wing Venture Capital, with participation from Afore Capital, J Ventures, and South Park Commons. The round brings the company's total funding to $17.6 million. Built with over a dozen purpose-built large language model pipelines, Develop Health is the first medication access platform fully architected around GenAI. Its EHR-integrated platform plugs into virtual care workflows to verify insurance coverage in real time, generate and submit the correct prior authorization package, follow up and track status continuously, and return structured data back into the provider's system, all without manual effort from care teams. Founded by Mel van Londen and Benjamin Easton, Develop Health is tackling a growing bottleneck in healthcare: the administrative complexity that delays access to necessary medications. Before Develop Health, the founders held roles at provider-facing healthcare startups Canvas Medical and Rupa Health, where they saw how poor communication and data fidelity between providers and payers led to delayed treatment, lost revenue, and worse outcomes for patients. 'We believe providers should be able to make care decisions with full visibility into a patient's plan, because a prescription that isn't affordable or accessible is no prescription at all,' said Mel van Londen, co-founder and CEO of Develop Health. 'We're building healthcare's agentic clearinghouse, starting with medication access and designing infrastructure that meets both payers and providers where they are.' The new funding will fuel Develop Health's expansion beyond its core work helping digital health companies navigate the pharmacy benefit space—spanning GLP-1s and treatments across addiction, neurology, dermatology, and psychiatry—into the medical benefit market. The company will also deepen its integrations with both EHRs and PBMs, streamlining and scaling the link between prescribing and coverage, and extend its reach into traditional providers outside of digital health. 'Develop Health is solving one of the most frustrating pain points in healthcare – getting patients the medications they need without weeks of paperwork and endless back-and-forth,' said Sara Choi, Partner at Wing Venture Capital. 'They've built a system that puts GenAI to work in one of the industry's most critical, overlooked workflows. Develop Health is positioned to become essential infrastructure for any provider dealing with medication access complexity. ' Today, Develop Health helps providers reduce churn, set clearer patient expectations, and streamline access to care. The platform reduces form completion time by over 80% and increases approval rates, improving both provider efficiency and patient experience. In just three months, the company has grown significantly and is on track to helping over 1 million patients access their medications by the end of this year. That traction has been driven by Develop Health's exceptional team of engineers, including Jack Collins, Juan de Urtubey, and Zygimantas Koncius, whose technical excellence has made the platform possible. About Develop Health Develop Health's mission is to empower providers by eliminating the friction of prior authorization and improving visibility into plan benefits—freeing up capacity to deliver truly high-quality patient care. At its core, Develop Health is healthcare's agentic clearinghouse, beginning with medication access. Today, the platform supports hundreds of thousands of patients each month in getting the treatments they need—while reducing administrative work related to medication access by 83%. Learn more at
